A Botox-Like Gel Could Be Here by 2019

By ·
A Botox-Like Gel Could Be Here by 2019 featured image

What once sounded like a fantasy, could soon be a reality.

ABC reports that a Northern California company, Revance Therapeutics, is already in Phase 3 trials, testing a topical method for administering botulinum toxin for the treatment of crow’s-feet. Its gel formula allows the ingredient to travel through the skin using peptides to deliver the wrinkle-smoothing benefits. Not only do the before-and-after photos look very convincing, but so far, the study shows results lasting twice as long as the three month period that neuromodulators such as Botox, Dysport and Xeomin provide.

You May Also Like: Botox Just Got a New Use Approved

Phase 2 trials of this drug showed that at four weeks, 88.9 percent of subjects achieved clinically relevant improvement in crow’s-feet lines.

“Botox-type gels are here,” says West Palm Beach, FL, dermatologist Kenneth R. Beer, MD. “There are two companies, Revance and Anterios (which was just acquired by Allergan), that have them. I was an investigator for Anterios, and in my opinion, they work. They’re not as good as injections because it’s harder to get something through the skin in large amounts with a gel or cream, but they do work.”

New York dermatologist Francesca Fusco, MD, adds, “I am looking forward to using the new ‘topical-tox.’ It’s only been tested on crow’s-feet so far, and I have many patients with fine crow’s-feet around their eyes who want a natural look, without swelling, bruising or a frozen look. Since it is topical, the risk of a droop or migration to a deeper muscle is minimized.”

A spokesperson for Revance tells NewBeauty that the company plans to commercialize the product and seek approval for the topical treatment for crow’s feet by 2019. 

Find a Doctor

Find a NewBeauty "Top Beauty Doctor" Near you

Give the Gift of Luxury

NewBeauty uses cookies for various reasons, including to analyze and improve its content and advertising. Please review our Privacy Policy and Terms of Use for more about how we use this data. By continuing to use this site, you agree to these policies.